Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction

Study Identifier
GMA-LUM-11-020
CT.gov Identifier
NCT01547598
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Open Angle
  • Ocular Hypertension
    • Study Drug
  • travoprost ophthalmic solution 0.004%
  • travoprost 0.004% / timolol 0.5% combination ophthalmic solution
  • Bimatoprost ophthalmic solution 0.01%
    • Phase
    Phase 4
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Open angle glaucoma or ocular hypertension * Best corrected visual acuity of 20/100 or better in both eyes
    Exclusion Criteria:
    * Ocular surgery within 3 months, or anticipated ocular surgery within 12 weeks * Previous treatment with LUMIGAN® RC or DuoTrav® * History of LASIK, LASEK, RK or PRK in the study eye(s) * Active ocular inflammation

    Protocol Summary

    This non-inferiority study will assess safety and efficacy of LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) versus DuoTrav® (travoprost 0.004%/timolol 0.5% combination ophthalmic solution) in patients previously on Travatan® Z (travoprost ophthalmic solution 0.004%) monotherapy.

    Study Locations

    Location
    Status
    Location
    Vancouver, British Columbia, Canada
    Status
    Not applicable